Journal article
HLA-B*5701 screening for susceptibility to abacavir hypersensitivity
Journal of Antimicrobial Chemotherapy, Vol.59(4), pp.591-593
04/2007
Abstract
The introduction of highly active antiretroviral therapy (also known as combination therapy) has transformed the nature of HIV infection from a severe and ultimately fatal disease to that of a manageable chronic condition. HIV drugs are highly efficacious, but their use comes at the cost of a range of drug-related adverse events, including severe drug hypersensitivity reactions (HSRs) that have been most notably associated with abacavir and nevirapine therapy. This article discusses the issues of pharmacogenetic screening, in the light of the strong genetic association of the HLA-B*5701 allele and the susceptibility to developing abacavir HSRs. It also presents the screening's impact on clinical practice and discusses the practical considerations that influence the introduction and cost-effectiveness of such screening.
Details
- Title
- HLA-B*5701 screening for susceptibility to abacavir hypersensitivity
- Authors/Creators
- A. Lucas (Author/Creator)D. Nolan (Author/Creator)S. Mallal (Author/Creator)
- Publication Details
- Journal of Antimicrobial Chemotherapy, Vol.59(4), pp.591-593
- Publisher
- Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy
- Identifiers
- 991005540608507891
- Copyright
- © The Author 2007.
- Murdoch Affiliation
- Centre for Clinical Immunology and Biomedical Statistics
- Language
- English
- Resource Type
- Journal article
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites
Metrics
35 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Domestic collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.265 Dermatology - Skin Allergies
- 1.265.1140 Drug Hypersensitivity
- Web Of Science research areas
- Infectious Diseases
- Microbiology
- Pharmacology & Pharmacy
- ESI research areas
- Pharmacology & Toxicology